Isomorphic Labs, a pharmaceutical startup spun off from Google's DeepMind, announced it has developed a pipeline of AI-designed drugs that are advancing toward human clinical trials. Speaking at WIRED Health in London, company president Max Jaderberg described the pipeline as "broad and exciting" and said it represents a collection of new medicines developed using artificial intelligence.

The announcement comes as the biotechnology sector faces mixed developments in experimental medical technologies. While AI-driven drug discovery appears to be gaining momentum, other cutting-edge approaches are encountering setbacks.

Two companies that were pursuing human embryo editing to prevent serious genetic diseases have recently shut down operations. Bootstrap Bio and Manhattan Genomics, both of which were working on techniques to modify human embryos, have ceased their activities.

Isomorphic Labs was established as a separate entity from DeepMind to focus specifically on applying AI to drug discovery and development. The company aims to use machine learning algorithms to identify and design new therapeutic compounds more efficiently than traditional pharmaceutical research methods.

The contrast between the progress in AI-driven drug development and the closure of embryo editing companies highlights the varying trajectories of different biotechnology approaches. While some experimental medical technologies face regulatory, technical, or commercial challenges, others like AI-assisted drug discovery appear to be advancing toward practical applications.